Patents by Inventor Daniel Sutherlin

Daniel Sutherlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240116872
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 11, 2024
    Applicants: GENENTECH, INC., CURIS, INC
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Publication number: 20220081423
    Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain.
    Type: Application
    Filed: May 26, 2021
    Publication date: March 17, 2022
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI, Zhiguo LIU, Wenfeng LIU, Ramsay BEVERIDGE, Jean-Philippe LECLERC, Alexandre LEMIRE, Liang ZHAO, Claudio STURINO
  • Publication number: 20220055977
    Abstract: The invention provides a method of treating a disease or condition in a mammal by administering a compound having the general formula I: or a pharmaceutically acceptable salt thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 24, 2022
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William HEMEON, Brian SAFINA, Daniel SUTHERLIN
  • Patent number: 11203572
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 21, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS, INC
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Steven McKerrall, Daniel Sutherlin
  • Patent number: 11130726
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 28, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William Hemeon, Brian Salvatore Safina, Daniel Sutherlin
  • Publication number: 20210171516
    Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 24, 2020
    Publication date: June 10, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Philippe BERGERON, Kristen BURFORD, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Abid HASAN, Kwong Wah LAI, Zhiguo LIU, Steven MCKERRALL, Teresa Phuongtram NGUYEN, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao WANG
  • Patent number: 11028075
    Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 8, 2021
    Assignee: Genentech, Inc.
    Inventors: Daniel Sutherlin, Steven McKerrall, Kwong Wah Lai, Zhiguo Liu, Wenfeng Liu, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
  • Publication number: 20210155588
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 3, 2020
    Publication date: May 27, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Steven MCKERRALL, Daniel SUTHERLIN
  • Publication number: 20210107895
    Abstract: The invention provides a compounds and salts that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 15, 2021
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI
  • Publication number: 20210093618
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 1, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Paul Robert BICHLER, Chien-An CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao SHENG, Shaoyi SUN, Andrew D. WHITE, Michael Scott WILSON, Alla Yurevna ZENOVA, Jiuxiang ZHU
  • Publication number: 20210070707
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 27, 2020
    Publication date: March 11, 2021
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Patent number: 10793550
    Abstract: The invention provides 4-piperidin-chroman-7-sulfonamide derivatives and salts thereof that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: October 6, 2020
    Assignee: GENENTECH, INC.
    Inventors: Daniel Sutherlin, Steven McKerrall, Kwong Wah Lai
  • Patent number: 10787446
    Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 29, 2020
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Philippe Bergeron, Kristen Burford, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Abid Hasan, Kwong Wah Lai, Zhiguo Liu, Steven McKerrall, Teresa Phuongtram Nguyen, Brian Safina, Daniel Sutherlin, Tao Wang
  • Patent number: 10766858
    Abstract: The invention provides compounds having the general formula I: (i) and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: September 8, 2020
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Steven McKerrall, Daniel Sutherlin
  • Publication number: 20200115354
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 16, 2020
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Michael Scott WILSON, Kwong Wah LAI, Philippe BERGERON, Birong ZHANG, Ramsay BEVERIDGE, Jean-Philippe LECLERC, Alexandre LEMIRE, Liang ZHAO, Claudio STURINO
  • Publication number: 20200108054
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: April 22, 2019
    Publication date: April 9, 2020
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Paul Robert BICHLER, Chien-An CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao SHENG, Shaoyi SUN, Andrew D. WHITE, Michael Scott WILSON, Alla Yurevna ZENOVA, Jiuxiang ZHU
  • Publication number: 20200087239
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: November 15, 2019
    Publication date: March 19, 2020
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William HEMEON, Brian Salvatore SAFINA, Daniel SUTHERLIN
  • Publication number: 20200017469
    Abstract: The invention provides 4-piperidin-chroman-7-sulfonamide derivatives and salts thereof that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.
    Type: Application
    Filed: March 22, 2018
    Publication date: January 16, 2020
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI
  • Publication number: 20200010420
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 9, 2020
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Patent number: 10457654
    Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 29, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Daniel Sutherlin, Steven McKerrall, Michael Scott Wilson, Kwong Wah Lai, Philippe Bergeron, Birong Zhang, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino